Corbus Announces Positive Data for CRB-913 Obesity Treatment

Corbus Pharmaceuticals reported positive topline data from its CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment. The trial demonstrated statistically significant and clinically meaningful weight loss at all three doses, with a mean weight loss of 5% at 12 weeks for the 60 mg dose. CRB-913 showed a favorable safety profile and fewer gastrointestinal adverse events compared to published data of oral GLP-1 drugs. The data supports CRB-913's potential to establish a new class of oral, non-incretin obesity medicines.